• Miguel Gil, Belén Oliva, Julia Timoner, Miguel A Maciá, Verónica Bryant, and Francisco J de Abajo.
• Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain. miguel.gil@bifap.org
• Br J Clin Pharmacol. 2011 Dec 1; 72 (6): 965-8.

AimInformation from the spontaneous reporting system raised the hypothesis of an increased risk of meningioma in patients treated with high doses of cyproterone acetate (CPA). The objective of this study was to test the hypothesis of an increased risk of meningioma among users of high dose CPA as compared with non-users in a medical records computerized database.MethodsA retrospective cohort study was performed in a Spanish primary care database (BIFAP). Meningioma incidence rates were compared in patients exposed to high dose CPA (users) with those non-exposed and with those exposed to low dose CPA. Poisson regression analysis was used to estimate the incidence rate ratios after adjusting for age and gender.ResultsAmong 2474 users of high dose cyproterone (6663 person-years) four meningioma cases were identified, resulting in an incidence rate (IR) of 60.0 (95% CI 16.4, 153.7) per 100,000 person-years, which was significantly higher than that observed among the non-users (IR 6.6; 95% CI 6.0, 7.3) and among women users of low dose cyproterone (IR 0.0, 95% CI upper limit 5.5). After adjusting for age and gender, patients exposed to high dose CPA showed an increased risk of meningioma of 11.4 (95% CI 4.3, 30.8) as compared with non-users.ConclusionsThe results of this study support the hypothesis that the exposure to high dose CPA increases the risk of meningioma.British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. No claim to original US government works.

36 keywords...

hide…